|Bid||31.00 x 1400|
|Ask||35.00 x 1300|
|Day's Range||31.21 - 33.11|
|52 Week Range||21.45 - 46.44|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.50|
Over the past few years, Cathie Wood's ARK Invest group of exchange-traded funds have delivered impressive gains. ARK Invest's most successful fund over the past year, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) has the best performer of the bunch with an incredible 80% gain over the past 12 months. On Jun. 3, 2021, the ARK Genomic Revolution ETF bought shares of these two clinical-stage biotechs.
Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Eastern Time.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...